Navigation Links
New genetic variant associated with prostate cancer in African-Americans
Date:10/31/2007

Two tiny genetic variations may provide the best clues yet for finding more precise ways to estimate prostate cancer risk and improve screening and early detection for men of African descent, report researchers from the University of Chicago and the Translational Genomics Research Institute, Phoenix, AZ, in the December 2007 issue of Genome Research, published early online.

The researchers set out to determine whether results from four previous studies that linked genetic variations on one region of chromosome 8 to increased prostate cancer risk among Caucasians were also valid for men of African heritage. In the process, however, they found an additional genetic variation among African American men that was an even stronger marker for cancer risk for these men. That variation is located within a gene that plays a role in DNA repair. A malfunction in DNA repair could contribute to cancer development.

"This finding emphasizes the importance of ancestry in studying genetics," said study author Rick Kittles, associate professor of medicine at the University of Chicago Medical Center. "Previous studies led us to one specific region of chromosome 8," he said. "Then this approach -- which took advantage of genetic differences among African American men, who are at very high risk for this type of cancer -- led us to a different locus within that region and directly to a gene of interest.

Prostate cancer is the most common male malignancy and the second leading cause of cancer death in men. According to the American Cancer Society, it will affect nearly 220,000 men in the United States in 2007 and claim the lives of more than 27,000. It disproportionately affects African Americans who "exhibit the highest rate worldwide," Kittles said.

In this study, research groups lead by Kittles and by John Carpten of the Translational Genomics Research Institute analyzed the region of chromosome 8 highlighted by the earlier studies done on
'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Mouse brain tumors mimic those in human genetic disorder
5. Genetically modified natural killer immune cells attack, kill leukemia cells
6. Scientists identify genetic pathways essential to RNA interference
7. Ants Genetic Engineering Leads To Species Interdependency
8. Researchers trace evolution to relatively simple genetic changes
9. Genetic Variation Visualization - From EMBL
10. Genetically modified rice in China benefits farmers health, study finds
11. Key mechanism in genetic inheritance during cell division identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... HOUSTON, Oct. 22, 2010 Researchers can spend entire ... efforts featured in the pages of Science , ... won,t be the case, though, for two junior faculty ... Jacinta Conrad and Jeff Rimer, both assistant ...
... LA Research conducted by scientists at LSU Health Sciences ... brain act as valves to turn the hormone that regulates ... may lead to advances in treatment for diseases like high ... The research is published in the November 1, 2010 issue ...
... received two grants from the California Institutefor Regenerative Medicine ... treating neurological diseases and liver failure. The goal of ... toward the development of potential therapies within the next ... successful, they could then be further prepared as potential ...
Cached Biology News:UH engineering professors featured in consecutive issues of Science 2UH engineering professors featured in consecutive issues of Science 3LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2UCSF stem-cell based-neurological, liver therapy strategies advanced 2UCSF stem-cell based-neurological, liver therapy strategies advanced 3UCSF stem-cell based-neurological, liver therapy strategies advanced 4
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... constant currency revenue growth of 12.9 percent,- Full year ... and improving profitability reflects success of strategic ... for fiscal year 2009, BATESVILLE, Ind., Nov. 10 ... financial results for its fiscal,fourth quarter ended September 30, ...
... Incorporated,(Nasdaq: SPEX ) reported that the Nasdaq Stock ... its common stock from the Nasdaq,Global Market to the ... trading on the Nasdaq Capital Market on November 11, ... three market tier designations for,Nasdaq-listed stocks, and presently includes ...
... Conference Call Today at 4:30 p.m. Eastern Time -, ... MDVN ) today reported on its corporate progress and ... "The third quarter represented another quarter of significant,achievement and ... partnering,agreement with Pfizer for Dimebon. This collaboration not only ...
Cached Biology Technology:Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19Spherix Transfers Stock Listing to Nasdaq Capital Market 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8
... StabilZyme AP Conjugate Stabilizer is ... purified bovine protein and other non-toxic ... (4-Morpholine-ethanesulfonic acid), pH 5.5 6.5. ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... When nonspecific binding is a ... a variety of immobilized NeutrAvidin products ... streptavidin. NeutrAvidin is a modified avidin ... to provide a biotin-binding protein with ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
... generated hybridomas against a large variety ... you are provided with personalized project ... lines developed by Covance remain exclusive ... hybridoma development project has four phases: ...
Biology Products: